Correlation Engine 2.0
Clear Search sequence regions

  • allergen (6)
  • autoantigen (7)
  • humans (1)
  • native (1)
  • Sizes of these terms reflect their relevance to your search.

    Antigen-specific immunotherapies (ASIT) present compelling potential for introducing precision to the treatment of autoimmune diseases where nonspecific, global immunosuppression is currently the only treatment option. Central to ASIT design is the delivery of autoantigen, which parallels allergy desensitization approaches. Clinical success in tolerizing allergen-specific responses spans longer than a century, but autoimmune ASITs have yet to see an FDA-approved breakthrough. Allergens and autoantigens differ substantially in physicochemical properties, and these discrepancies influence the nature of their interactions with the immune system. Approved allergen-specific immunotherapies are typically administered as water soluble, neutrally charged protein fractions from 10 to 70 kDa. Conversely, autoantigens are native proteins that exhibit wide-ranging sizes, solubilities, and charges that render them susceptible to immunogenicity. To translate the success of allergen hyposensitization to ASIT, delivery strategies may be necessary to effectively format autoantigens, guide biodistribution, and engage appropriate immune mechanisms. Copyright © 2020 Elsevier B.V. All rights reserved.


    J Daniel Griffin, Jimmy Y Song, Joshua O Sestak, Brandon J DeKosky, Cory J Berkland. Linking autoantigen properties to mechanisms of immunity. Advanced drug delivery reviews. 2020;165-166:105-116

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 32325104

    View Full Text